$MNKD Two relatively recent studies on AFREZZA h
Post# of 128
(Total Views: 5335)
Posted On: 01/17/2017 3:42:08 PM
$MNKD Two relatively recent studies on AFREZZA
https://www.ncbi.nlm.nih.gov/pubmed/27333446 and https://t.co/HgktstVq0W
The first study concluded, "
CONCLUSION:
In-silico clinical trials comparing the treatment effect of different dosing regimens with TI and of insulin lispro suggest that postmeal dosing or split dosing of TI, in combination with an appropriate titration rule, can achieve a superior postprandial glucose control while providing a lower risk for hypoglycemic events than conventional treatment with subcutaneously administered rapid-acting insulin products." (emphasis added)
(copy) by Hypi
https://www.ncbi.nlm.nih.gov/pubmed/27333446 and https://t.co/HgktstVq0W
The first study concluded, "
CONCLUSION:
In-silico clinical trials comparing the treatment effect of different dosing regimens with TI and of insulin lispro suggest that postmeal dosing or split dosing of TI, in combination with an appropriate titration rule, can achieve a superior postprandial glucose control while providing a lower risk for hypoglycemic events than conventional treatment with subcutaneously administered rapid-acting insulin products." (emphasis added)
(copy) by Hypi
(1)
(0)MannKind Corporation (MNKD) Stock Research Links
$MJ
Scroll down for more posts ▼